Treatment for MCI: is the evidence sufficient?

Neurology

Volumn 70, Issue 22, 2008, Pages 2020-2021

  Aisen, Paul S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GALANTAMINE; ALPHA TOCOPHEROL; CHOLINESTERASE INHIBITOR; DONEPEZIL; ROFECOXIB;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; HUMAN; METHODOLOGY; NOTE; PSYCHOLOGICAL ASPECT; AMYLOIDOSIS; CHEMICAL ANALYSIS; DISEASE COURSE; DRUG MEGADOSE; EDITORIAL; FOLLOW UP; GENETIC SUSCEPTIBILITY; HIGH RISK POPULATION; MILD COGNITIVE IMPAIRMENT; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SOCIAL BEHAVIOR; TREATMENT PLANNING;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; GALANTAMINE; HUMANS;

EID: 47049095382     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000313380.89894.54     Document Type: Editorial

References (4)

1. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379-2388.
2. Feldman HH, Ferris S, Winblad B, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer’s disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007;6:501-512.
3. Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005;30:1204-1215.
4. Winblad B, Gauthier S, Scinto L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008;70:2024-2035.